• Savas Sencan, Ozge Kenis-Coskun, Fatma Gul Ulku Demir, Isa Cuce, Tulay Ercalık, and Osman Hakan Gunduz.
• Department of Physical Medicine and Rehabilitation, Division of Pain Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.
• Neurol Neurochir Pol. 2018 Sep 1; 52 (5): 612-617.

Aim Of The StudyTo define the effectiveness of ganglion Impar block in improving neuropathic pain.Materials And MethodsPatients who had pain around the coccyx for more than three months and did not respond to conservative treatment were included in this study. All the patients underwent fluoroscopy guided transsacrococcygeal ganglion Impar block with injecting 3 mL of 0.5% bupivacaine, 2 mL saline, and 1 mL (40 mg) of methylprednisolone. Patients were evaluated with visual analog scale (VAS) for pain, Leeds assessment of neuropathic symptoms and signs scale (LANSS) for neuropathic pain, Beck depression Inventory (BDI) for mood and Short-form 12 (SF-12) for quality of life before, 1 month 3 months and 6 months after the injection. Patients' painless sitting duration was also recorded.ResultsA total of 28 patients were included in the final analyses. VAS and LANSS scores improved significantly throughout the follow-up periods. BDI scores also improved while SF-12 scores did not show significant changes. Painless sitting period of the patients' improved significantly.ConclusionsGanglion Impar block is effective in decreasing the neuropathic component of chronic coccygodynia. This improves painless sitting in patients but its reflections on quality of life is not clear.Copyright © 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.

11 keywords...

hide…